216 related articles for article (PubMed ID: 17472819)
1. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids.
Hodder R; Kesten S; Menjoge S; Viel K
Int J Chron Obstruct Pulmon Dis; 2007; 2(2):157-67. PubMed ID: 18044688
[TBL] [Abstract][Full Text] [Related]
3. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.
Donohue JF; Hanania NA; Make B; Miles MC; Mahler DA; Curry L; Tosiello R; Wheeler A; Tashkin DP
Chest; 2014 Dec; 146(6):1531-1542. PubMed ID: 25451347
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.
Tashkin DP; Doherty DE; Kerwin E; Matiz-Bueno CE; Knorr B; Shekar T; Banerjee S; Staudinger H
Int J Chron Obstruct Pulmon Dis; 2012; 7():43-55. PubMed ID: 22334768
[TBL] [Abstract][Full Text] [Related]
5. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
Koch A; Pizzichini E; Hamilton A; Hart L; Korducki L; De Salvo MC; Paggiaro P
Int J Chron Obstruct Pulmon Dis; 2014; 9():697-714. PubMed ID: 25045258
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: phase III study results.
Bogdan MA; Aizawa H; Fukuchi Y; Mishima M; Nishimura M; Ichinose M
BMC Pulm Med; 2011 Nov; 11():51. PubMed ID: 22085439
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.
Cope S; Zhang J; Williams J; Jansen JP
BMC Pulm Med; 2012 Jun; 12():29. PubMed ID: 22732017
[TBL] [Abstract][Full Text] [Related]
8. Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol.
Ganapathy V; Stensland MD
Int J Chron Obstruct Pulmon Dis; 2017; 12():1793-1801. PubMed ID: 28694692
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.
Cope S; Donohue JF; Jansen JP; Kraemer M; Capkun-Niggli G; Baldwin M; Buckley F; Ellis A; Jones P
Respir Res; 2013 Oct; 14(1):100. PubMed ID: 24093477
[TBL] [Abstract][Full Text] [Related]
10. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study.
Stockley RA; Chopra N; Rice L
Thorax; 2006 Feb; 61(2):122-8. PubMed ID: 16443706
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study.
Jenkins CR; Jones PW; Calverley PM; Celli B; Anderson JA; Ferguson GT; Yates JC; Willits LR; Vestbo J
Respir Res; 2009 Jun; 10(1):59. PubMed ID: 19566934
[TBL] [Abstract][Full Text] [Related]
12. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes.
Anzueto A; Leimer I; Kesten S
Int J Chron Obstruct Pulmon Dis; 2009; 4():245-51. PubMed ID: 19657398
[TBL] [Abstract][Full Text] [Related]
13. Dose-response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT).
Beeh KM; Emirova A; Prunier H; Santoro D; Nandeuil MA
Int J Chron Obstruct Pulmon Dis; 2018; 13():1701-1711. PubMed ID: 29872288
[TBL] [Abstract][Full Text] [Related]
14. Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study.
Whale CI; Sovani MP; Mortimer KJ; Harrison TW; Tattersfield AE
Br J Clin Pharmacol; 2008 Jun; 65(6):841-7. PubMed ID: 18394012
[TBL] [Abstract][Full Text] [Related]
15. Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.
Beeh KM; LaForce C; Gahlemann M; Wenz A; Toorawa R; Fležar M
Respir Res; 2015 Jul; 16(1):87. PubMed ID: 26177937
[TBL] [Abstract][Full Text] [Related]
16. Role of arformoterol in the management of COPD.
King P
Int J Chron Obstruct Pulmon Dis; 2008; 3(3):385-91. PubMed ID: 18990965
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat
Koch A; Watz H; Maleki-Yazdi MR; Bothner U; Tetzlaff K; Voß F; McGarvey L
NPJ Prim Care Respir Med; 2017 Oct; 27(1):60. PubMed ID: 29061968
[TBL] [Abstract][Full Text] [Related]
18. ADRB2 polymorphisms and budesonide/formoterol responses in COPD.
Bleecker ER; Meyers DA; Bailey WC; Sims AM; Bujac SR; Goldman M; Martin UJ
Chest; 2012 Aug; 142(2):320-328. PubMed ID: 22383665
[TBL] [Abstract][Full Text] [Related]
19. Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis.
Watz H; Rickard K; Rheault T; Bengtsson T; Singh D
Int J Chron Obstruct Pulmon Dis; 2020; 15():2199-2206. PubMed ID: 32982212
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.
Leaker BR; Barnes PJ; Jones CR; Tutuncu A; Singh D
Br J Clin Pharmacol; 2015 Mar; 79(3):492-500. PubMed ID: 25243340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
